1026785-55-6
1026785-55-6
Chemical Structure
Lomibuvir
Synonym(s): VX-222
- CAS No.: 1026785-55-6
- Formula:C25H35NO4S
- Molecular Weight:445.61
IUPAC Name: 5-(3,3-dimethylbut-1-yn-1-yl)-3-((1r,4R)-N-((1r,4R)-4-hydroxycyclohexyl)-4-methylcyclohexane-1-carboxamido)thiophene-2-carboxylic acid
InChIKey: WPMJNLCLKAKMLA-VVPTUSLJSA-N
SMILES: O=C(C1=C(N([C@@H]2CC[C@@H](O)CC2)C([C@H]3CC[C@H](C)CC3)=O)C=C(C#CC(C)(C)C)S1)O
Biological Activity: Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lomibuvir | 99.71% | Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lomibuvir (Standard) | ≥98% | Lomibuvir (Standard) is the analytical standard of Lomibuvir. This product is intended for research and analytical applications. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
cis-Lomibuvir | cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis. cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VX-759 | VX-759 (VCH-759) is an orally active HCV NS5B RNA-dependent RNA polymerase inhibitor. VX-759 is promising for research of chronic hepatitis C. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Transcainide | Transcainide (R 54718) is an orally active antiarrhythmic agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
COR628 | COR628 is a positive allosteric modulator of GABA(B) receptors with the activity of enhancing GABA-induced GTPγS stimulation. COR628 showed significant activity in in vitro studies but did not exhibit endogenous agonist activity. COR628 has shown efficacy in experiments in mice by enhancing the sedation/hypnosis induced by baclofen, shortening the onset time and extending the duration of loss of righting reflex when combined with non-sedating doses of baclofen . The cytotoxic effect of COR628 is comparable to or higher than that of GS39783 or BHF177 in concentration. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VCH-916 | 98.38% | VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VCH-916 free base | VCH-916 free base is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase. VCH-916 free base binds to Thumb Site II. VCH-916 free base can be used for the research of hepatitis c virus (hcv) infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Boc-bipiperidine-ethynylbenzoic acid | 99.02% | Boc-bipiperidine-ethynylbenzoic acid is an Alkyl/ether-based PROTAC linker can be used in the synthesis of ARD-61. Boc-bipiperidine-ethynylbenzoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lasmotinib | 98.16% | Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax (HY-15531) or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Radalbuvir | Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC50 = 2.9 nM, GT1b EC50 = 6 nM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-((3S,3aS,5aS,6R,9aS,9bS)-3-(Tert-butylcarbamoyl)-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid (Standard) | ≥98% | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
